UNSPSC 51314327: Brompheniramine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314327 Brompheniramine/pseudoephedrine is a Commodity code with limited direct relevance to recent state and local procurement activity. The three most recent opportunities posted under this code—a Seminole County naloxone and drug deactivation systems IFB, a Texas HHS Commission RFI on direct-to-manufacturer prescription programs, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—involve pharmaceutical procurement broadly but do not specifically target brompheniramine/pseudoephedrine products. The naloxone solicitation focuses on opioid-reversal agents and drug deactivation systems; the Texas RFI explores pharmacy benefit program structure and direct contracting models rather than specific drug products; and the MMCAP RFP seeks comprehensive generic and OTC pharmaceutical lines through authorized wholesalers without naming individual active pharmaceutical ingredients. State and local issuers soliciting under this code span county health departments (Seminole County, Florida), state HHS commissions (Texas), and multistate cooperative purchasing alliances (Minnesota), indicating that pharmaceutical procurement runs across diverse jurisdictions and administrative models.

Recent activity is concentrated in Florida, Texas, and Minnesota. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, requiring fixed-fee pricing and E-Verify compliance. The Texas HHS Commission RFI (HHS0017013, posted April 3, 2026) was exploratory, gathering vendor capability data on direct-to-manufacturer prescription models before formal RFP issuance. The MMCAP RFP (S1070000015802, due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products across Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), requiring cGMP and Drug Supply Chain Security Act compliance, with pricing weighted at 75 percent of evaluation and a 3 percent administrative fee on contract purchases. The code shows little specific recent activity targeting brompheniramine/pseudoephedrine as a discrete procurement line.